Azithromycin dispersible tablets is a macrolide antibacterial drug with good safety profile and rare serious adverse reactions. It belongs to grade B in pregnancy classification and animal experiments have shown no effect on the fetus, but there is a lack of experience in its application in human pregnant women. It is well tolerated by patients and the incidence of adverse reactions is low. Gastrointestinal reactions account for most of the adverse reactions. The main symptoms include diarrhea (loose stools), epigastric discomfort (pain or cramping), nausea, vomiting, and occasionally abdominal distention. They are generally mild to moderate. Some side effects have been shown during clinical trials and in reports after the product has been marketed, but causality has not been established. However, they should still be taken seriously. Adverse events are as follows: palpitations and arrhythmias, including ventricular tachycardia, have been reported; dizziness/vertigo, convulsions, headache, drowsiness, sensory abnormalities, increased activity; generalized weakness; others are candidiasis, allergy (rarely fatal); interstitial nephritis and acute failure; thrombocytopenia; abnormal liver function, occasionally causing hepatic necrosis and liver failure, but rarely fatal; arthralgia; aggressive reactions neuroticism, anxiety, apprehension; vaginitis; allergic reactions such as painful itching, rash, photosensitivity, edema, urticaria, vascular decompensation; hearing impairment loss, tinnitus and/or deafness; rare reports of taste changes due to azithromycin; blood leukocytes/reticuloendothelial system, pro-neutropenia